Coalition for Epidemic Preparedness Innovations

Fondazione Biotecnopolo di Siena is a private, non-profit foundation with a registered office and operations to develop applied research and innovation in the field of biotechnology and life sciences.

Micron Biomedical is a clinical-stage biopharmaceutical company established in 2014 and located in Atlanta, Georgia. The company focuses on developing microneedle patches specifically for vaccines, including those for influenza and polio. Its innovative microneedle technology aims to improve protective and therapeutic effects while enhancing patient compliance and simplifying the administration process. By leveraging this technology, Micron Biomedical seeks to facilitate the development of effective vaccines, addressing important public health needs.

We are developing a global information exchange platform to accelerate the availability of safe and effective medicines.

Valneva is a pharmaceutical company specializing in the development of prophylactic vaccines aimed at addressing infectious diseases with significant unmet medical needs. The company has successfully commercialized several vaccines, including IXIARO/JESPECT, DUKORAL, and IXCHIQ, primarily targeting travelers. In addition to its marketed products, Valneva is advancing a diverse pipeline of vaccine candidates, including those for Lyme disease, chikungunya, and COVID-19. The company is involved in the entire lifecycle of vaccine development, encompassing research, manufacturing, and distribution. Valneva also offers technologies and services aimed at enhancing vaccine commercialization, which further supports its mission to deliver life-saving immunizations globally.

Apriori Bio is a health security company dedicated to protecting humanity from viral threats. It employs a unique technology platform that surveys the landscape of existing and potential viral variants, enabling the design of variant-resilient vaccines and antibody drugs. By providing real-time insights, Apriori Bio aims to prepare for future outbreaks and ensure durable protection against rapidly evolving viruses. The company's innovative approach focuses on developing effective solutions to combat both current and emerging viral challenges.

BioNTech is a biotechnology company based in Germany that specializes in developing innovative therapies for cancer and infectious diseases, including COVID-19. The company is known for its focus on individualized immunotherapy and has a diverse oncology pipeline that features various classes of drugs, such as mRNA-based therapeutics that encode antigens and neoantigens, as well as cytokines, antibodies, cell therapies, bispecific antibodies, and antibody-drug conjugates. BioNTech's notable achievement includes the commercialization of its COVID-19 vaccine, Comirnaty. Additionally, the company collaborates with several major pharmaceutical firms, enhancing its capabilities and reach in the biopharmaceutical industry.

aVaxziPen is a clinical-stage pharmaceutical company dedicated to developing innovative drug-device combination products, with a primary focus on next-generation vaccines targeting infectious diseases and emerging pathogens. The company employs its proprietary ImplaVax solid dose formulation and device technology to create novel solid dose vaccines aimed at addressing a variety of infectious and select diseases. By enhancing the performance and delivery of vaccines and therapeutics, aVaxziPen supports medical researchers in their efforts to advance these products to human clinical trials, thereby contributing to the overall progress in the field of vaccine development and infectious disease management.

Aspen Pharmacare Holdings Limited is a global pharmaceutical company headquartered in Durban, South Africa, specializing in the manufacture and supply of both branded and generic pharmaceutical products. It operates primarily through two segments: Commercial Pharmaceuticals and Manufacturing. Aspen offers a diverse range of products, including general anaesthetics, muscle relaxants, cytotoxic medications, and injectable anticoagulants, particularly focusing on low molecular weight heparins and Xa inhibitors. The company also engages in the contract production and supply of active pharmaceutical ingredients (APIs) and finished pharmaceuticals for third parties. With a presence in over 150 countries, Aspen serves various markets, including South Africa, Australia, and several nations across Europe and Asia. Its extensive capabilities in manufacturing encompass both API and finished dosage forms, addressing a wide array of therapeutic needs. Founded in 1850, Aspen has expanded its reach significantly through strategic acquisitions, enhancing its footprint in emerging markets and contributing to a diverse portfolio of healthcare solutions.

SK Bioscience is a South Korean pharmaceutical company focused on the development and manufacturing of vaccines. The company is notable for introducing SKYCellflu, the first cell culture influenza vaccine in Korea, and has since expanded its portfolio to include the SKYCellflu Quadrivalent prefilled syringe and a 13-valent Pneumococcal Conjugate Vaccine. In addition to these licensed products, SK Bioscience is actively engaged in the development of several other vaccines, including a recombinant rotavirus vaccine, a new typhoid conjugate vaccine, and an innovative pneumococcal vaccine, often in collaboration with external partners. The company is dedicated to building a robust infrastructure for continuous vaccine development, positioning itself as a key player in the global vaccine landscape.

Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.

The Sabin Vaccine Institute is dedicated to enhancing vaccine accessibility and promoting immunization, particularly in low- and middle-income populations that are disproportionately affected by infectious diseases. The organization focuses on developing innovative vaccines aimed at preventing a wide range of illnesses, ensuring that these vital health resources are available to communities worldwide. By emphasizing the importance of immunization coverage, the Sabin Vaccine Institute seeks to improve overall healthcare outcomes and contribute to the prevention of diseases on a global scale.

NEC OncoImmunity AS is a bioinformatics company based in Oslo, Norway, specializing in machine-learning software solutions aimed at enhancing cancer immunotherapy. Founded in 2014 and a subsidiary of NEC Corporation since 2019, the company focuses on identifying immunogenic neoantigens to improve personalized cancer treatments. Its platform supports patient selection for immunotherapy by determining optimal neoantigen targets for personalized vaccines and cell therapies within a clinically actionable timeframe. By providing tools that address critical knowledge gaps, NEC OncoImmunity enables healthcare institutions and research organizations to advance the development of effective neoantigen-based immunotherapies and biomarkers for cancer treatment.

DIOSynVax is a vaccine antigen design company that focuses on accelerating vaccine development to enhance protection against both existing and emerging pathogens. By utilizing innovative technology, DIOSynVax digitally designs, optimizes, and synthesizes vaccines, leading to significant advancements in immunization against diseases such as influenza, COVID-19, and viral hemorrhagic fevers. The company's approach aims to improve the efficacy of vaccines, enabling healthcare professionals to treat patients more effectively and facilitate quicker recovery from various viral infections.

Clover Biopharmaceuticals is a clinical-stage biotechnology company dedicated to discovering, developing, and commercializing innovative biologic therapies primarily targeting oncology and autoimmune diseases. The company employs its proprietary Trimer-Tag technology platform to create novel biologics that focus on trimerization-dependent pathways. In addition to its therapeutic efforts, Clover is also engaged in the development of select biosimilars, utilizing its in-house cGMP biomanufacturing capabilities. The company aims to address unmet medical needs in both infectious diseases and cancer through its advanced vaccine and therapeutic candidates.

Vaccine and Infectious Disease Organization (VIDO) at the University of Saskatchewan is a world leader in developing vaccines and technologies against infectious diseases.

MigVax Ltd. is an Israeli medical technology startup focused on the development, manufacture, and commercialization of vaccines targeting viruses affecting humans. Based in Kiryat Shmona, Israel, the company is a subsidiary of MIGAL - Galilee Research Institute LTD. MigVax is engaged in creating vaccines for various diseases, including a vaccine for the infectious bronchitis virus and others that address avian coronaviruses, which share similar infection mechanisms with human coronaviruses. This innovative approach enables medical practitioners to effectively combat a range of viral diseases.

Dynavax Technologies Corporation is a biopharmaceutical company based in Emeryville, California, focused on developing and commercializing innovative vaccines. The company's primary product, HEPLISAV-B, is an approved hepatitis B vaccine designed to prevent infection from all known subtypes of the virus in adults aged 18 and older. Dynavax is also advancing its proprietary CpG 1018 adjuvant to enhance vaccine efficacy and is engaged in various collaborations aimed at developing adjuvanted vaccines for COVID-19, pertussis, and universal influenza. In addition to its commercial efforts, Dynavax is involved in research partnerships with organizations such as Clover Biopharmaceuticals, the University of Queensland, and the Coalition for Epidemic Preparedness Innovations to create new vaccine candidates. The company was originally founded in 1996 as Double Helix Corporation and rebranded to its current name in September 1996.

Bharat Biotech Ltd. is a biotechnology company headquartered in Hyderabad, India, specializing in the research, development, and manufacture of vaccines and biotherapeutics. The company produces a range of vaccines, including Revac-B+, a recombinant hepatitis-B vaccine; TYPBAR, a typhoid vaccine; BIOPOLIO, a poliomyelitis vaccine; INDIRAB, a rabies vaccine; and BioHib, a haemophilus influenza type b vaccine. Additionally, Bharat Biotech offers biotherapeutics such as REGEN-D, a recombinant human epidermal growth factor gel for diabetic foot ulcers and burns, and various women’s healthcare products, including human chorionic gonadotrophin and menotropin. The company exports its products to several countries, including Kenya, Zambia, and the Philippines. Incorporated in 1996, Bharat Biotech aims to provide affordable and effective solutions for neglected diseases, contributing to global health improvements.

Novavax, Inc. is a late-stage biotechnology company focused on the discovery, development, and commercialization of vaccines aimed at preventing serious infectious diseases. Its lead vaccine candidates include ResVax, designed to protect infants from respiratory syncytial virus (RSV) through maternal immunization, and NanoFlu, targeted at treating seasonal influenza in older adults. Both candidates utilize Novavax's proprietary Matrix-M adjuvant to enhance immune responses. In addition, the company is advancing an RSV F vaccine for older adults and children, and it is developing nanoparticle vaccines against the Ebola virus and a combination respiratory vaccine for influenza and RSV. Novavax is also working on a COVID-19 vaccine, NVX-CoV2373, in collaboration with Takeda Pharmaceutical Company for development and commercialization. Established in 1987 and headquartered in Gaithersburg, Maryland, Novavax utilizes its recombinant technology platform to create highly immunogenic nanoparticles to address urgent global health needs.

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development, and commercialization of DNA medicines aimed at treating, curing, and preventing diseases associated with human papillomavirus (HPV), cancer, and various infectious diseases. The company's proprietary SynCon immunotherapy design enhances the immune response against cancerous cells and provides broad protection against multiple pathogens. Inovio is actively conducting clinical studies for its DNA medicines, particularly for HPV-related precancers and cancers, as well as other diseases such as glioblastoma, prostate cancer, HIV, and COVID-19. Its lead candidate, VGX-3100, is in Phase 3 trials for treating precancerous cervical dysplasia linked to high-risk HPV types. The company has established partnerships with various organizations, including major pharmaceutical companies and research institutions, to advance its research and development efforts. Founded in 1979 and headquartered in Plymouth Meeting, Pennsylvania, Inovio Pharmaceuticals is recognized for its innovative approach to immunotherapy and gene therapy.

Themis Bioscience N.V. is a clinical-stage biopharmaceutical company based in Vienna, Austria, specializing in immunomodulation to develop products aimed at protecting against infectious diseases. Founded in 2009, the company’s lead candidate, MV-CHIK, has successfully completed Phase II clinical trials for chikungunya treatment. Themis is also advancing vaccines targeting other infectious diseases, including Zika virus, Lassa fever, and MERS, along with developing therapeutics for cancer. Themis has established a research collaboration and exclusive licensing agreement with Merck & Co., enhancing its capabilities and market reach. The company is focused on progressing its innovative vaccine candidates through various clinical development phases while positioning itself as a valuable partner in the biotech and pharmaceutical sectors.

Novavax, Inc. is a late-stage biotechnology company focused on the discovery, development, and commercialization of vaccines aimed at preventing serious infectious diseases. Its lead vaccine candidates include ResVax, designed to protect infants from respiratory syncytial virus (RSV) through maternal immunization, and NanoFlu, targeted at treating seasonal influenza in older adults. Both candidates utilize Novavax's proprietary Matrix-M adjuvant to enhance immune responses. In addition, the company is advancing an RSV F vaccine for older adults and children, and it is developing nanoparticle vaccines against the Ebola virus and a combination respiratory vaccine for influenza and RSV. Novavax is also working on a COVID-19 vaccine, NVX-CoV2373, in collaboration with Takeda Pharmaceutical Company for development and commercialization. Established in 1987 and headquartered in Gaithersburg, Maryland, Novavax utilizes its recombinant technology platform to create highly immunogenic nanoparticles to address urgent global health needs.

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development, and commercialization of DNA medicines aimed at treating, curing, and preventing diseases associated with human papillomavirus (HPV), cancer, and various infectious diseases. The company's proprietary SynCon immunotherapy design enhances the immune response against cancerous cells and provides broad protection against multiple pathogens. Inovio is actively conducting clinical studies for its DNA medicines, particularly for HPV-related precancers and cancers, as well as other diseases such as glioblastoma, prostate cancer, HIV, and COVID-19. Its lead candidate, VGX-3100, is in Phase 3 trials for treating precancerous cervical dysplasia linked to high-risk HPV types. The company has established partnerships with various organizations, including major pharmaceutical companies and research institutions, to advance its research and development efforts. Founded in 1979 and headquartered in Plymouth Meeting, Pennsylvania, Inovio Pharmaceuticals is recognized for its innovative approach to immunotherapy and gene therapy.

Themis Bioscience N.V. is a clinical-stage biopharmaceutical company based in Vienna, Austria, specializing in immunomodulation to develop products aimed at protecting against infectious diseases. Founded in 2009, the company’s lead candidate, MV-CHIK, has successfully completed Phase II clinical trials for chikungunya treatment. Themis is also advancing vaccines targeting other infectious diseases, including Zika virus, Lassa fever, and MERS, along with developing therapeutics for cancer. Themis has established a research collaboration and exclusive licensing agreement with Merck & Co., enhancing its capabilities and market reach. The company is focused on progressing its innovative vaccine candidates through various clinical development phases while positioning itself as a valuable partner in the biotech and pharmaceutical sectors.

Themis Bioscience N.V. is a clinical-stage biopharmaceutical company based in Vienna, Austria, specializing in immunomodulation to develop products aimed at protecting against infectious diseases. Founded in 2009, the company’s lead candidate, MV-CHIK, has successfully completed Phase II clinical trials for chikungunya treatment. Themis is also advancing vaccines targeting other infectious diseases, including Zika virus, Lassa fever, and MERS, along with developing therapeutics for cancer. Themis has established a research collaboration and exclusive licensing agreement with Merck & Co., enhancing its capabilities and market reach. The company is focused on progressing its innovative vaccine candidates through various clinical development phases while positioning itself as a valuable partner in the biotech and pharmaceutical sectors.